Urovant Sciences (NASDAQ:UROV) Rating Lowered to Sell at Zacks Investment Research

Share on StockTwits

Urovant Sciences (NASDAQ:UROV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “

UROV has been the subject of a number of other reports. HC Wainwright set a $28.00 price objective on shares of Urovant Sciences and gave the stock a “buy” rating in a research report on Monday, October 21st. ValuEngine cut shares of Urovant Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Urovant Sciences presently has an average rating of “Hold” and an average target price of $21.44.

Shares of UROV traded down $0.34 during trading hours on Wednesday, hitting $9.62. The stock had a trading volume of 51,500 shares, compared to its average volume of 55,316. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.20 and a current ratio of 6.20. The firm has a 50-day moving average price of $9.64 and a 200 day moving average price of $8.57. Urovant Sciences has a fifty-two week low of $4.05 and a fifty-two week high of $14.49. The firm has a market capitalization of $293.09 million, a price-to-earnings ratio of -2.17 and a beta of 1.66.

Urovant Sciences (NASDAQ:UROV) last posted its earnings results on Tuesday, November 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.30. As a group, analysts predict that Urovant Sciences will post -4.02 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of UROV. Perceptive Advisors LLC raised its position in Urovant Sciences by 116.7% during the second quarter. Perceptive Advisors LLC now owns 1,875,426 shares of the company’s stock worth $14,835,000 after acquiring an additional 1,010,067 shares during the period. FMR LLC raised its position in Urovant Sciences by 28.4% during the first quarter. FMR LLC now owns 1,710,836 shares of the company’s stock worth $17,194,000 after acquiring an additional 378,135 shares during the period. Atria Investments LLC acquired a new position in Urovant Sciences during the second quarter worth $3,420,000. LVW Advisors LLC acquired a new position in Urovant Sciences during the third quarter worth $372,000. Finally, Marshall Wace LLP acquired a new position in Urovant Sciences during the first quarter worth $325,000. Institutional investors own 24.23% of the company’s stock.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Recommended Story: Outstanding Shares

Get a free copy of the Zacks research report on Urovant Sciences (UROV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.